3 Results for "

preclinical cellular models

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "preclinical cellular models" in MCE Product Catalog:

3
Trastuzumab vedotin
Trastuzumab vedotin
0 Images
3 Cited Publications
Cat. No.: HY-164992
Synonyms: MRG002; Trastuzumab MMAE
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
loading...
    loading...
View All Sizes
2'-Deoxy-PTX
2'-Deoxy-PTX
0 Images
Cat. No.: HY-185269
CAS No.: 156413-68-2
Target:  

Microtubule/Tubulin Drug Derivative

Research Areas:  

Cancer

2'-Deoxy-PTX is a Paclitaxel (HY-B0015) derivative and microtubule assembly inducer. 2'-Deoxy-PTX binds to GMPcPP-stabilized microtubules, with a Kaapp of 0.50 × 10 6 M -1. 2′-Deoxy-PTX induces Tubulin to assemble into normal microtubules. 2'-Deoxy-PTX can be used for the research of prostate cancer .
loading...
    loading...
View All Sizes
Anti-Aging Compound Library Mini
Anti-Aging Compound Library Mini
0 Images
Cat. No.: HY-L034M
381 compounds

Research has shown that drugs targeting aging pathways demonstrate promising potential in models of age-related diseases such as Alzheimer's disease, cardiovascular diseases, metabolic syndrome, osteoarthritis, and various malignancies. This suggests that intervening in the biological processes of aging may enable synergistic prevention and treatment of multiple chronic diseases. Against the backdrop of the gradual elucidation of core aging mechanisms-including cellular senescence, telomere attrition, epigenetic dysregulation, and chronic inflammation anti-aging research has shifted from traditional phenotypic interventions toward targeting key pathways that regulate biological age.

The MCE Anti-Aging Compound Library Mini is precisely built upon this cutting-edge concept. It focuses on aging-related targets validated through genetic or functional studies, comprising 381 compounds designed to provide systematic research tools for aging biology and intervention strategy development. The library covers core mechanisms such as mTOR, SIRT, energy metabolism, clearance of senescent cells, optimization of mitochondrial function, and telomere maintenance. For each target, 1-5 compounds with clear activity and strong representativeness have been carefully selected, spanning the entire translational spectrum from preclinical tool molecules to clinically investigational drugs.

Assay Types